KSQ Therapeutics, Douglas Pagán and Beni Wolf

KSQ Therapeutics fills the positions of CFO and CMO, with the appointments of Douglas Pagán (pictured, left​) and Beni Wolf (pictured, right​), respectively.

According to the company, it is working towards advancing its first program into the clinic in 2020, which will utilise CRISPR technology for the treatment of solid tumours.

Pagán joins the company after having previously been the CFO for Paratek Pharmaceuticals for four years, as well as a director of finance for Biogen for a similar amount of time and six years at Johnson & Johnson, as a marketing research associate.

While Wolf arrives from Blueprint Medicines, where he was SVP for clinical development for four years. He also spent seven years working at Genentech, where he ended his time associate medical director, and worked as medical director at Amgen.

“I believe that KSQ’s CRISPRomics approach holds tremendous potential for developing high-impact cancer medicines that can set new standards in the field of oncology,”​ said Wolf.

CRISPRomics is the name given to KSQ’s drug discovery engine, which has allowed the biotech to develop a pipeline of over a dozen investigational drug targets.